DGAP-News

Fresenius Medical Care AG & Co. KGaA reports strong start to the year 2016 - Seite 2

exchange effects in all segments outside North America as well as higher
legal and consulting expenses.

Net income attributable to shareholders of Fresenius Medical Care AG & Co.
KGaA for the first quarter of 2016 was $228 million, a strong increase of
9% compared to $210 million of last year's first quarter. Based on a number
of approximately 305.3 million shares (weighted average number of shares
outstanding), basic earnings per share (EPS) for the first three months
2016 amounted to $0.75, compared to $0.69 for the first quarter of 2015.

Segment development
North America revenue increased by 10% to $3,044 million (72% of total
revenue). Dialysis business grew by 8%, Care Coordination increased by 20%.
The continued progress in Care Coordination was driven by organic growth of
+17% and reached $522 million in revenues. Dialysis growth was positively
influenced by a higher volume with commercial payors, two more dialysis
days and increased product sales (especially machines and dialyzers).

The substantially improved dialysis operating income margin of 16.9% (+300
basis points compared to Q1 2015) was due to lower costs from Health Care
supplies, a favourable impact from commercial payors as well as decreased
legal expenses. Total operating income (EBIT) for the quarter under review
was $436 million, an impressive increase of 28%. Total operating income
margin improved to 14.3%.

EMEA revenue increased by 5% to $631 million at constant currency. Positive
business movements from an increase in dialysis treatments were offset by
the negative currency impact, especially due to the strong US Dollar. Also
product revenue came in with a 5% plus at constant currency ($330 million)
due to increased sales of bloodlines, products for acute care treatments
and hemodialysis solutions and concentrates. Operating income of $130
million in Q1 2016 was negatively impacted mainly due to the weakening of
various local currencies.

Asia Pacific grew by 10% at constant currency to $374 million. The region
recorded $168 million in Net Health Care revenue, based on an increase of
6% in dialysis treatments. With a growth of +16% at constant currency to
$206 million, the product business showed a very strong sales performance
in dialysers, bloodlines, machines and peritoneal dialysis products.
Operating income decreased to $65 million (-23%) and was impacted by
unfavorable foreign exchange effects, increased costs related to further
sales development and costs associated with changes in the Management
Board.

Latin America delivered revenue of $153 million, an improvement of 5% at
constant currency (-23% on a reported basis). In addition to the negative